Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Galantamine in AD
Neurol 54:2261-2268, Raskind,M.A.,et al, 2000
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Advanced Dementia
NEJM 372:2533-2540, Mitchell, S.L., 2015
Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Memantine for Dementia in Adults Older than 40 years with Downs Syndrome (MEADOWS): a Randomised,double-blind,placebo-controlled Trial
Lancet 379:528-536, Hanney,M.,et al, 2012
Donepezil and Memantine for Moderate-to Severe Alzheimers Disease
NEJM 366:893-903,957, Howard,R.,et al, 2012
Effectiveness of Adding Memantine to an Alzheimer Dementia Treatment Regimen Which Already Includes Stable Donepezil Therapy: A Critically Appraised Topic
The Neurologist 17:121-123, Riordan,K.C.,et al, 2011
A Randomized, Double-Blind, Placebo Controlled Trial of Simvastatin to Treat Alzheimer Disease
Neurol 77:556-563, Sano, M.,et al, 2011
Early Alzheimers Disease
NEJM 362:2194-2201, Mayeux,R., 2010
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
Disease-Modifying Therapies for Alzheimers: New Drugs on the Horizon
Practical Neurology 7:16-23, Christensen,D.B., 2008
Phase 2 Safety Trial Targeting Amyloid � Production With a ?-Secretase Inhibitor in Alzheimer Disease
Arch Neurol 65:1031-1038, Fleisher,A.S.,et al., 2008
Effect of Demebon on Cognition, Activities of Daily Living, Behavior, and Global Function in Patients With Mild-To-Moderate Alzheimers Disease: A Randomised, Double-Blind, Placebo-Controlled Study
Lancet 372:207-215,179, Doody, R.S.,et al., 2008
Alternative Medicine and Alzheimer Disease
The Neurologist 14:299-306, Kelley,B.J. &Knopman,D.S., 2008
Donepezil Preserves Cognition and Global Function in Patients With Severe Alzheimer Disease
Neurol 69:459-469, Black,S.E.,et al, 2007
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Coxibs and Alzheimers Disease: Should They Stay or Should They Go?
Ann Neurol 59:219-228, Firuzi,O. &Pratico,D., 2006
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Arch Neurol 63:49-54, Reisberg,B.,et al, 2006
Effect of Enhanced Psychosocial Care on Antipsychotic Use in Nursing Home Residents with Severe Dementia; Cluster Randomised Trial
BMJ 332:756-758,741, Fossey,J.,et al, 2006
Donepezil in Patients with Severe Alzheimers Disease: Double-Blind, Parallel-Group, Placebo-Controlled Study
Lancet 367:1057-1065,1031, Winblad,B.,et al, 2006
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy
Arch Neurol 62:721-728, Mega,M.S.,et al, 2005
Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease
Arch Neurol 62:753-757, Sparks,D.L.,et al, 2005
Cholinesterase Inhibitors for Patients with Alzheimers Disease: Systematic Review of Randomised Clinical Trials
BMJ 331:321-323, Kaduszkiewicz,H.,et al, 2005
Lipid Lowering Agents Are Associated With a Slower Cognitive Decline in Alzheimers Disease
JNNP 76:1624-1629, Masse,I.,et al, 2005
Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil, A Randomized Controlled Trial
JAMA 291:317-324, Tariot,P.N.,et al, 2004
Size of the Treatment Effect on Cognition of Cholinesterase Inhibition in Alzheimer's Disease
JNNP 75:677-685, Rockwood,K., 2004
Alzheimer's Disease
NEJM 351:56-67, Cummings,J.L, 2004
The Efficacy of Donepezil in the Treatment of Neuropsychiatric Symptoms in Alzheimer Disease
Neurol 63:214-219,200, Holmes,C.,et al, 2004
Atypical Antipsychotic Drugs in the Treatment of Behavioural and Psychological Symptoms of Dementia: Systematic Review
BMJ 329:75-78, Lee,P.E.,et al, 2004
Long-term Donepezil Treatment in 565 Patients with Alzheimer's Disease (AD2000): Randomised Double-Blind Trial
Lancet 363:2105-2115,2100, AD2000 Collaborative Group, 2004
Economic Evaluation of Donepezil in Moderate to Severe Alzheimer Disease
Neurol 63:644-650, Feldman,H.,et al, 2004
Efficacy of Cholinesterase Inhibitors in the Treatment of Neuropsychiatric symptoms and Functional Impairment in Alzheimer Disease
JAMA 289:210-216, Trinh,N.,et al, 2003
Acetylcholinesterase Inhibitors for Vascular Dementia and Alzheimer's Disease Combined With Cerebrovascular Disease
Stroke 34:584-586, Bowler,J.V., 2003
DHEA Treatment of Alzheimer's Disease
Neurol 60:1071-1076,1060, Wolkowitz,O.M.,et al, 2003
Memantine in Moderate-to-Severe Alzheimer's Disease
NEJM 348:1333-1341, Reisberg,B.,et al, 2003
Early Alzheimer's Disease
NEJM 349:1056-1063, Kawas,C.H., 2003
Donepezil is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease
Am Geriatr Soc 51:937-944, Geldmacher,D.S.,et al, 2003
Exercise Plus Behavioral Management in Patients with Alzheimer's Disease
JAMA 290:2015-2022, Teri,L.,et al, 2003